Davis Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$312 Hold
1
– – ﹤0.01% 744
2026
Q2
$316 Buy
+1
New +$236 ﹤0.01% 719

Other funds holding LGND

Davis Capital Management's LGND Position: Q3 2026 in Review

Davis Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q3 2026 at 1 share worth $312. The position accounts for ﹤0.01% of the portfolio, ranked #744.

Davis Capital Management first reported a position in LGND in Q2 2026 and has held it in 2 quarters since. The position peaked at $316 in Q2 2026. 433 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Davis Capital Management held 1 share of Ligand Pharmaceuticals worth $312 as of Q3 2026.
  • Davis Capital Management left its Ligand Pharmaceuticals share count unchanged in Q3 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #744 holding.
  • Davis Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Davis Capital Management's Ligand Pharmaceuticals position peaked at $316 in Q2 2026.
  • 433 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.